Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (2024)

Table of Contents
Novavax is a 'super volatile stock,' strategist explains COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights Novavax quarterly revenue misses estimate on weak COVID vaccine sales Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024 Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine Novavax Submits Application to U.S. FDA for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine Novavax stock rises on COVID vaccine delivery projections My Novavax stock price forecast was correct: what next now? FDA advisers urge targeting JN.1 strain in fall's COVID vaccines Novavax to Participate in 2024 Jefferies Global Healthcare Conference Novavax awaits FDA decision on whether its next COVID shot can be offered in US Shah Capital ends campaign against Novavax board after Sanofi deal Up 3x In A Week Will Novavax Stock Continue To See Higher Levels? Levi & Korsinsky, LLP Notifies Shareholders of Novavax, Inc. (NVAX) an Upcoming Claims Deadline in a Class Action Settlement Novavax to Participate in BofA Securities 2024 Health Care Conference Novavax stock jumps 50% as Sanofi deal kicks off turning point for struggling vaccine maker Novavax Surges on $1.2 Billion Sanofi Vaccine Deal Novavax (NVAX) Deal with Sanofi to Co-Commercialize Covid Vaccine Novavax stock soars on $1.2 billion Sanofi vaccine deal Novavax Stock Doubles on $1.2B Sanofi Deal for COVID-19, Flu Vaccines Novavax Shares Surge Over 140% After $1.4 Billion Covid Shot Deal With Sanofi Novavax Gets $1.4 Billion Deal With Sanofi. The Stock Jumps. Novavax shares jump 40% on $1.2 billion licensing deal with Sanofi despite Q1 losses Novavax shares surge on new $1.4 billion deal with Sanofi FAQs References

Novavax is a 'super volatile stock,' strategist explains

Novavax (NVAX) recently reported its second quarter results, missing estimates on revenue and adjusted earnings while slashing its full-year outlook for revenue. Despite this, Novavax's stock edges hi...

4 days ago - Yahoo Finance

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (1)

COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit

On Thursday, Novavax Inc NVAX reported second-quarter 2024 sales of $415 million, compared to$424 milliona year, missing the consensus of $458.6 million.

4 days ago - Benzinga

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (2)

Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights

Achieved total revenue of $415 million in the second quarter of 2024 and ended the period with $1.1 billion in Cash Filed with theU.S. FDA and EMA for authorization of updated 2024-2025 formula COVID...

4 days ago - PRNewsWire

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (3)

Novavax quarterly revenue misses estimate on weak COVID vaccine sales

Novavax reported second-quarter revenue that was below analysts' estimates on Thursday due to lower-than-expected sales of its COVID-19 vaccine.

5 days ago - Reuters

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (4)

Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024

GAITHERSBURG, Md. , Aug. 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its second ...

11 days ago - PRNewsWire

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (5)

Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine

Novavax's JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 GAITHERSBURG, Md. , June 24, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company ...

7 weeks ago - PRNewsWire

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (6)

Novavax Submits Application to U.S. FDA for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine

Novavax's updated JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 Novavax's JN.1 COVID-19 vaccine would be the only protein-based option available in the U...

2 months ago - PRNewsWire

Novavax stock rises on COVID vaccine delivery projections

Shares of Novavax (NVAX) are surging after the company announced it will meet delivery expectations for the fall COVID vaccine push. All COVID vaccines will use the JN.1 strain, part of the Omicron su...

2 months ago - Yahoo Finance

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (7)

My Novavax stock price forecast was correct: what next now?

Novavax (NASDAQ: NVAX) stock price has gone parabolic this year, making it one of the best-performing companies in New York. It has soared by over 335% in 2024 and by almost 500% from its lowest level...

2 months ago - Invezz

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (8)

FDA advisers urge targeting JN.1 strain in fall's COVID vaccines

WASHINGTON — Government advisers Wednesday said it's time to update the recipe for the COVID-19 vaccines Americans will receive in the fall — targeting a version of the ever-evolving coronavirus calle...

Other symbols: MRNAPFE

2 months ago - Market Watch

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (9)

Novavax to Participate in 2024 Jefferies Global Healthcare Conference

GAITHERSBURG, Md. , May 30, 2024 /PRNewswire/ --Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the...

2 months ago - PRNewsWire

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (10)

Novavax awaits FDA decision on whether its next COVID shot can be offered in US

Novavax will only be able to offer a COVID-19 vaccine in the United States this autumn if regulators accept the shot it has started manufacturing that targets a variant that was dominant earlier this ...

2 months ago - Reuters

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (11)

Shah Capital ends campaign against Novavax board after Sanofi deal

Hedge fund Shah Capital said on Monday it would withdraw its campaign against the re-election of three directors on Novavax's board, after the COVID-19 vaccine maker struck a licensing deal with Sanof...

Other symbols: SNY

3 months ago - Reuters

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (12)

Up 3x In A Week Will Novavax Stock Continue To See Higher Levels?

The stock price of Novavax (NASDAQ: NVAX), a Covid-19 vaccine developer, trades at $13 per share, about 96% below its peak level of $320 seen in February 2021. NVAX stock was trading at around $51 in ...

3 months ago - Forbes

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (13)

Levi & Korsinsky, LLP Notifies Shareholders of Novavax, Inc. (NVAX) an Upcoming Claims Deadline in a Class Action Settlement

NEW YORK, NY / ACCESSWIRE / May 16, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Novavax, Inc. (NASDAQ:NVAX). The settlem...

3 months ago - Accesswire

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (14)

Novavax to Participate in BofA Securities 2024 Health Care Conference

GAITHERSBURG, Md. , May 13, 2024 /PRNewswire/ --Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the...

3 months ago - PRNewsWire

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (15)

Novavax stock jumps 50% as Sanofi deal kicks off turning point for struggling vaccine maker

Novavax said the deal with Sanofi allows it to remove its "going concern" warning, which it first issued last year due to doubts about staying afloat.

Other symbols: SNY

3 months ago - CNBC

Novavax Surges on $1.2 Billion Sanofi Vaccine Deal

Novavax shares soared after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Madison Muller reports on Bloomberg Televi...

Other symbols: SNY

3 months ago - Bloomberg Markets and Finance

Novavax (NVAX) Deal with Sanofi to Co-Commercialize Covid Vaccine

Novavax (NVAX) signed a deal with drugmaker Sanofi to co-commercialize the Covid Vaccine. Diane King Hall discusses this, as well as Novavax's 1Q earnings.

Other symbols: SNY

3 months ago - Schwab Network

Novavax stock soars on $1.2 billion Sanofi vaccine deal

Novavax (NVAX) shares are skyrocketing after announcing a $1.2 billion deal with Sanofi (SNY) to commercialize a combined COVID-19 and flu shot. Yahoo Finance's Anjalee Khemlani joins The Morning Brie...

Other symbols: SNY

3 months ago - Yahoo Finance

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (16)

Novavax Stock Doubles on $1.2B Sanofi Deal for COVID-19, Flu Vaccines

Novavax (NVAX) shares more than doubled in intraday trading Friday after announcing a $1.2 billion deal to license its vaccine technology to French drugmaker Sanofi (SNY).

Other symbols: SNY

3 months ago - Investopedia

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (17)

Novavax Shares Surge Over 140% After $1.4 Billion Covid Shot Deal With Sanofi

Shares for Novavax swelled by more than 140% Friday morning, after the biotech firm announced a $1.4 billion deal with Sanofi to commercialize its Covid vaccine and develop a new combination shot for ...

3 months ago - Forbes

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (18)

Novavax Gets $1.4 Billion Deal With Sanofi. The Stock Jumps.

The two companies will also work on a shot that combines Covid-19 and flu vaccines.

Other symbols: SNY

3 months ago - Barrons

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (19)

Novavax shares jump 40% on $1.2 billion licensing deal with Sanofi despite Q1 losses

Novavax (NASDAQ:NVAX) shares rocketed 40% in premarket trading Friday, driven not only by the company's fiscal Q1 2024 earnings report but more significantly, by a crucial multi-billion dollar deal wi...

Other symbols: SNY

3 months ago - Invezz

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (20)

Novavax shares surge on new $1.4 billion deal with Sanofi

Novavax on Friday said it had struck a $1.4 billion deal with Sanofi to commercialize its existing COVID-19 vaccine and develop a new combined jab to inoculate against both the coronavirus and influen...

Other symbols: SNY

3 months ago - Market Watch

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis (2024)

FAQs

Novavax, Inc. (NVAX) Stock Price, Quote & News - Stock Analysis? ›

Novavax's analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.

What are analysts saying about Novavax? ›

Novavax's analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.

What is the prediction for Novavax stock? ›

Based on short-term price targets offered by six analysts, the average price target for Novavax comes to $18.17. The forecasts range from a low of $9.00 to a high of $31.00. The average price target represents an increase of 43.75% from the last closing price of $12.64.

Is Novavax a buy hold or sell? ›

Is Novavax stock a Buy, Sell or Hold? Novavax stock has received a consensus rating of buy. The average rating score is and is based on 6 buy ratings, 2 hold ratings, and 2 sell ratings. What was the 52-week low for Novavax stock?

What are analyst targets for NVAX? ›

Stock Price Targets
High$31.00
Median$18.00
Low$9.00
Average$18.17
Current Price$11.60

Is Novavax stock a buy zacks? ›

Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Novavax is rated Zacks Rank #3 (Hold).

What is special about Novavax? ›

The power & speed of nanoparticle technology. Our vaccine technology combines power and speed with the immunogenicity-enhancing properties of our Matrix-M™ adjuvant to efficiently produce highly immunogenic particles targeting some of the most pressing viral infectious diseases.

Who owns the most Novavax stock? ›

What percentage of Novavax (NVAX) stock is held by retail investors? According to the latest TipRanks data, approximately 50.14% of Novavax (NVAX) stock is held by retail investors. Who owns the most shares of Novavax (NVAX)? Vanguard owns the most shares of Novavax (NVAX).

Is Novavax being shorted? ›

Related Stocks

More important to investors may be the fact that over 36% of Novavax shares are now being held short, including over half traded off listed exchanges.

Will Novavax be used in the US? ›

Novavax intends to provide doses of our 2024-2025 COVID-19 vaccine at the start of the vaccination season and upon EUA by the U.S. Food and Drug Administration (FDA). When authorized, our vaccine will be the only protein-based option available in the U.S. for individuals aged 12 and older.

What is the forecast for Novavax in 2025? ›

Novavax Stock Prediction 2025

The Novavax stock prediction for 2025 is currently $ 36.51, assuming that Novavax shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a 214.75% increase in the NVAX stock price.

What is the debt of Novavax? ›

Total debt on the balance sheet as of March 2024 : $0.22 B

According to Novavax's latest financial reports the company's total debt is $0.22 B.

Is NVAX a dividend stock? ›

Novavax (NASDAQ: NVAX) does not pay a dividend.

What is the stock price prediction for Novavax in 2024? ›

Novavax Stock Price Forecast 2024-2025

The forecasted Novavax price at the end of 2024 is $15.92 - and the year to year change +232%. The rise from today to year-end: +11%.

What is the analyst price Target for a stock? ›

A price target is a price at which an analyst believes a stock to be fairly valued relative to its projected and historical earnings. When an analyst raises their price target for a stock, they generally expect the stock price to rise.

What is NVAX 50 day moving average? ›

Novavax 50-day simple moving average is 14.21 while NVAX share price is 12.16, making it a Sell technically. NVAX stock price is 12.16 and Novavax 200-day simple moving average is 7.97, creating a Buy signal.

What are the concerns with Novavax COVID vaccine? ›

Possible side effects: Injection site tenderness, fatigue, headache, muscle pain. There were rare cases of myocarditis and pericarditis (six cases in 40,000 participants) in the clinical trial.

What are the CDC recommendations for Novavax? ›

‡12 years and older: People aged 12 years and older who have not previously gotten any COVID-19 vaccine doses and choose to get Novavax should get 2 doses of updated Novavax vaccine to be up to date.

What is the difference between Novavax and other vaccines? ›

Novavax is a traditional protein subunit vaccine. While each of the authorized vaccines works to help our body's immune system recognize and attack the COVID-19 virus, Novavax utilizes an older, more familiar vaccine technology.

References

Top Articles
Latest Posts
Recommended Articles
Article information

Author: Jamar Nader

Last Updated:

Views: 6174

Rating: 4.4 / 5 (75 voted)

Reviews: 82% of readers found this page helpful

Author information

Name: Jamar Nader

Birthday: 1995-02-28

Address: Apt. 536 6162 Reichel Greens, Port Zackaryside, CT 22682-9804

Phone: +9958384818317

Job: IT Representative

Hobby: Scrapbooking, Hiking, Hunting, Kite flying, Blacksmithing, Video gaming, Foraging

Introduction: My name is Jamar Nader, I am a fine, shiny, colorful, bright, nice, perfect, curious person who loves writing and wants to share my knowledge and understanding with you.